- Home
- KALV vs LYEL Comparison
KALV vs LYEL Comparison
Compare KALV & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KALV | LYEL |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.2M | 504.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | KALV | LYEL |
|---|---|---|
| Price | $16.12 | $25.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $30.00 | $25.00 |
| AVG Volume (30 Days) | ★ 1.3M | 92.1K |
| Earning Date | 03-11-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,426,000.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $204.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.74 | $7.65 |
| 52 Week High | $19.00 | $45.00 |
Technical Indicators
Market Signals| Indicator | KALV | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 54.89 | 45.86 |
| Support Level | $15.22 | $23.00 |
| Resistance Level | $16.16 | $26.02 |
| Average True Range (ATR) | 0.88 | 1.74 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 76.95 | 43.74 |
Price Performance
Historical ComparisonAbout KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.